Form 4: Aquestive Therapeutics CFO A. Ernest Toth Jr. Reports Stock Transactions
SEC Form 4 Filing
A. Ernest Toth Jr., CFO of Aquestive Therapeutics, reports acquisition and disposal of common stock and stock options.
Summary
- A. Ernest Toth Jr., the Chief Financial Officer of Aquestive Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 7, 2025, Toth acquired 110,000 shares of common stock and disposed of 10,193 shares to cover tax obligations related to vesting Restricted Stock Units (RSUs).
- On March 9, 2025, Toth disposed of 8,736 shares to cover tax obligations related to vesting Restricted Stock Units (RSUs).
- Toth also acquired 60,000 non-qualified stock options exercisable at $2.65, vesting in three annual installments, and expiring on March 7, 2035.
- Following these transactions, Toth directly owns 339,366 shares of common stock and 60,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing primarily reflects routine transactions related to compensation and tax obligations. The acquisition of shares is mildly positive, but the disposal for tax purposes offsets some of that positivity.
Positives
- The acquisition of 110,000 shares of common stock by the CFO could be seen as a positive signal.
Negatives
- The disposal of shares to cover tax obligations, while common, reduces the CFO's holdings.
Risks
- Tax obligations arising from vesting RSUs may lead to further disposal of shares.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in financial analysis.
- Comparing the CFO's transactions to those of peers in similar pharmaceutical companies can provide insights into the relative attractiveness of Aquestive Therapeutics' stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the CFO's actions.
Key Dates
| Date | Description |
|---|---|
| 03/07/2025 | Acquisition of 110,000 common stock shares and disposal of 10,193 shares for tax obligations; Grant of 60,000 non-qualified stock options. |
| 03/09/2025 | Disposal of 8,736 shares for tax obligations. |
| 03/11/2025 | Date of signature by Attorney-In-Fact. |
| 03/07/2035 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.